Glaxo to submit Relovair to regulatory authorities
Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-a-day respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
Anglo-American drugs giant GlaxoSmithKline and US counterpart Theravance said the phase III registration programme for the once-a-day respiratory medicine, Relovair, in patients with chronic obstructive pulmonary disease (COPD) has been completed.
Additionally, all but one of the pivotal studies in patients with asthma have been completed.
For COPD, Glaxo intends to submit regulatory applications in the US and Europe in mid-2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
For asthma, Glaxo plans to submit an application in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication.
The COPD programme included two 52-week "exacerbation" studies, each of which randomised approximately 1,620 patients. In the two studies in the COPD programme Relovair at all doses performed better than its comparator Vilanterol. Despite the success Glaxo is investigating reports of fatal pneumonia amongst patients who used Relovair, primarily at the 200/25mcg dose.
The asthma study programme is still waiting on results comparing the efficacy of Relovair against fluticasone propionate and a placebo. That study is expected to complete in the first half of 2012.
Glaxo admits a 24 week "superiority study" of Relovair against Seretide in asthma patients "did not meet the predefined threshold for superiority". Glaxo describes this study as "non-pivotal".
In the last 12 months GlaxoSmithKline shares have climbed 21%.
BS
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Government launches full review of parental leave and pay – what could it mean for you?
The government wants parental leave to be fairer - will its shake-up fix the widespread problem for families?
-
Nationwide: House prices see biggest monthly fall in over two years
UK house prices dropped by 0.8% in June, according to Nationwide. We reveal the top-performing and worst-performing regions